Guideline for diagnosis and comprehensive treatment of colorectal liver metastases (version 2025).
10.3760/cma.j.cn441530-20250713-00265
- Collective Name:Chinese College of Surgeons;Section of Gastrointestinal Surgery, Branch of Surgery, Chinese Medical Association;Section of Colorectal Surgery, Branch of Surgery, Chinese Medical Association;Colorectal Cancer Professional Committee, Chinese Anti‐Cancer Association;Colorectal Cancer Professional Committee, Chinese Medical Doctor Association;Colorectal Cancer Expert Committee, Chinese Society of Clinical Oncology;Chinese Society of Colon & Rectal Surgeons, Chinese College of Surgeons, Chinese Medical Doctor Association;Metastasis Research Committee, Anorectal Branch of Chinese Medical Doctor Association;Section of Colorectal Oncology, Oncology Branch, Chinese Medical Association;Branch of Metastatic Tumor Therapy, China International Exchange and Promotive Association for Medical and Health Care;Branch of Colorectal Disease, China International Exchange and Promotive Association for Medical and Health Care
- Publication Type:English Abstract
- MeSH:
Humans;
Liver Neoplasms/diagnosis*;
Colorectal Neoplasms/therapy*;
Liver Transplantation;
Practice Guidelines as Topic
- From:
Chinese Journal of Gastrointestinal Surgery
2025;28(8):815-831
- CountryChina
- Language:Chinese
-
Abstract:
The liver is the main target organ for hematogenous metastases from colorectal cancer, and colorectal liver metastasis is one of the most difficult and challenging situations in the treatment. In order to improve the diagnosis and comprehensive treatment in China, the Guidelines have been edited and revised for seven times since 2008, including the overall evaluation, personalized treatment goals and comprehensive treatments, to prevent the occurrence of liver metastases, increase the local damage rate of liver metastases, prolong long-term survival, and improve quality of life. The revised Guideline version 2025 includes the diagnosis and follow-up, prevention, multidisciplinary team (MDT), surgery and local ablative treatment, neoadjuvant and adjuvant therapy, comprehensive treatment. The revised Guideline emphasizes precision treatment based on genetic molecular typing, especially recommending immune checkpoint inhibitors for dMMR/MSI-H patients, and enriched local treatment methods, such as liver transplantation, yttrium-90 microsphere selective internal radiotherapy, etc. The revised Guideline includes state-of-the-art experience and findings, detailed content, and strong operability.
